Showing results (251-260 of 584) with videos related to
Sort By:
Pageof 59
Translational Lung Cancer Research|July 23, 2021
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 26, 2011
Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTLAurélie Durgeau, Faten El Hage, Isabelle Vergnon, et al.Clinical Lung Cancer|March 26, 2017
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613Jordi Remon, Jessica Menis, Baktiar Hasan, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 12, 2014
Synaptic release of CCL5 storage vesicles triggers CXCR4 surface expression promoting CTL migration in response to CXCL12Katarzyna Franciszkiewicz, Marie Boutet, Ludiane Gauthier, et al.Respiratory Medicine and Research|November 12, 2022
Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitorsMarion Camard, Benjamin Besse, Pierre-Louis Cariou, et al.Cancers|March 13, 2024
Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric ExperienceBaptiste Bonnet, Louis Tournier, Frédéric Deschamps, et al.American Journal of Clinical Oncology|August 8, 2006
Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II studyDavid Planchard, Hugues Bourgeois, Michèle Adoun, et al.Bulletin Du Cancer|October 10, 2014
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]Clarisse Audigier-Valette, Nicolas Girard, Alexis B Cortot, et al.Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.Pageof 59